Cosmos Health Inc. COSM
Cosmos Health Inc. was incorporated in 2009 in Nevada and is a diversified, vertically integrated global healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of innovative medicines and repurposing drugs as well as operator of a telehealth platform.
As a global company we are harnessing our expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern pharmaceutical and nutraceutical products.
We operate in the healthcare sector and particularly in the Pharmaceutical and Nutraceutical businesses. We cover vertically several process phases within the abovementioned sectors, such as research & development, manufacturing, marketing, sales and distribution of products and services. More specifically, we operate in generic medicines, nutraceuticals, biocides, medical devices, novel oncology drugs, drug repurposing and telehealth services.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $54.4M | $53.4M | $50.3M | $56.2M | $55.4M | $39.7M | $37.1M | $30.0M | $6.8M |
| Cost of revenue | $57.4M | $50.1M | $49.0M | $44.4M | $47.9M | $47.3M | $36.0M | $34.7M | $28.1M | $6.2M |
| Gross profit | $7.9M | $4.3M | $4.3M | $6.0M | $8.3M | $8.1M | $3.7M | $2.4M | $2.0M | $601.0K |
| R&D | $519.4K | $533.3K | $164.9K | — | — | — | — | — | — | — |
| SG&A | $15.6M | $11.7M | $19.6M | $10.2M | $9.2M | $2.1M | $3.3M | $3.6M | $4.9M | $794.1K |
| Total operating expenses | $24.6M | $19.9M | $26.2M | $13.4M | $12.9M | $5.3M | $3.9M | $3.6M | $6.8M | $803.5K |
| Operating income | -$16.7M | -$15.5M | -$21.8M | -$7.5M | -$4.5M | $2.7M | -$255.8K | -$1.2M | -$4.9M | -$202.5K |
| Interest expense | $1.9M | $1.0M | $866.5K | $2.3M | $2.8M | $2.8M | $1.4M | $967.8K | $748.5K | $189.7K |
| Pre-tax income | -$19.1M | -$16.2M | -$18.5M | -$13.1M | -$7.8M | $1.2M | -$3.1M | -$9.0M | -$6.2M | -$600.2K |
| Income tax | $0 | $0 | $0 | $775.1K | $114.0K | $377.5K | $182.8K | $17.3K | $2.8K | $769 |
| Net income | -$19.1M | -$16.2M | -$18.5M | -$13.8M | -$8.0M | $820.8K | -$3.3M | -$9.1M | -$6.2M | -$601.0K |
| EPS, basic | -0.63 | -1.17 | -2.15 | -33.16 | -23.74 | 0.06 | -0.25 | -0.68 | -0.49 | 0.00 |
| EPS, diluted | -0.63 | -1.17 | -2.15 | -33.16 | -23.74 | 0.06 | -0.25 | -0.68 | -0.49 | 80,741.00 |
| Shares, diluted (wtd. avg.) | $30.3M | $19.1M | $12.0M | $1.9M | $656.9K | $13.3M | $13.3M | $13.3M | $12.8M | $12.6M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $715.7K | $315.1K | $3.8M | $20.7M | $286.5K | $628.4K | $38.5K | $864.3K | $782.9K | $716.6K |
| Short-term investments | $46.2K | $21.1K | $20.1K | $14.9K | $11.5K | $222.8K | $238.9K | $2.7M | — | — |
| Receivables | $19.6M | $13.5M | $19.8M | $23.7M | — | — | — | $4.8M | $1.3M | $661.9K |
| Inventory | $5.8M | $4.4M | $4.8M | $3.5M | $3.1M | $3.3M | $3.5M | $3.2M | — | — |
| Total current assets | $38.4M | $25.5M | $36.6M | $56.4M | $39.8M | $40.8M | $21.2M | $18.3M | $9.5M | $2.6M |
| Property, plant and equipment | $10.6M | $9.7M | $10.3M | $1.8M | $1.9M | $1.8M | $1.7M | $1.4M | $114.6K | $52.7K |
| Goodwill | $49.7K | $49.7K | $49.7K | $49.7K | $49.7K | $49.7K | $49.7K | $49.7K | — | — |
| Other intangibles | $7.5M | $7.7M | $7.8M | $657.2K | $436.1K | $180.8K | $214.0K | $247.1K | — | — |
| Total assets | $65.5M | $54.3M | $66.0M | $68.0M | $49.4M | $43.8M | $23.9M | $20.7M | $10.7M | $3.1M |
| Accounts payable | $14.6M | $11.2M | — | — | — | $12.0M | $7.8M | $5.9M | $10.0M | $2.9M |
| Short-term debt | — | — | — | — | $578.9K | — | — | — | — | — |
| Total current liabilities | $38.3M | $25.8M | $24.3M | $21.7M | $29.9M | $34.3M | $28.2M | $22.3M | $13.7M | $4.9M |
| Long-term debt | $3.8M | $4.1M | $4.6M | $5.0M | $477.6K | $10.8M | $0 | $145.5K | — | — |
| Total liabilities | $47.1M | $29.8M | $30.0M | $28.4M | $45.0M | $48.0M | $30.3M | $24.0M | $13.7M | $4.9M |
| Retained earnings | -$133.2M | -$114.0M | -$91.6M | -$66.2M | -$34.3M | -$18.8M | -$19.6M | -$16.3M | -$7.2M | -$1.0M |
| Total equity | $18.4M | $24.5M | $36.0M | $39.3M | $4.4M | -$4.2M | -$6.5M | -$3.3M | -$3.0M | -$1.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.4M | -$7.7M | -$15.6M | -$14.9M | -$7.1M | -$11.5M | -$4.8M | -$1.6M | -$8.8M | -$2.1M |
| Depreciation and amortisation | $1.4M | $1.2M | $353.0K | $70.1K | $352.4K | $240.9K | $201.0K | $34.6K | $17.4K | $9.4K |
| Stock-based compensation | $2.3M | $1.7M | $577.9K | $24.4K | $5.9M | — | — | $242.0K | $338.8K | $16.6K |
| Capital expenditure | $55.7K | $418.1K | $1.3M | $74.2K | $581.4K | $117.7K | — | $503.4K | $55.3K | $12.8K |
| Investing cash flow | -$2.0M | -$798.3K | -$13.8M | -$21.5K | -$826.8K | -$117.7K | $588.9K | -$195.8K | -$14.5K | -$144.7K |
| Financing cash flow | $14.1M | $5.0M | $12.7M | $35.0M | $7.3M | $12.5M | $3.6M | $2.0M | $9.3M | $2.7M |
| Buybacks | — | $0 | $100.5K | — | $376.9K | $200.0K | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002278.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $105.86B | 23.7x | 12.4% |
| COR | Cencora, Inc. | $63.15B | 41.6x | 9.3% |
| CAH | CARDINAL HEALTH INC | $57.49B | 34.2x | 14.2% |
| HLF | HERBALIFE LTD. | $1.30B | 5.6x | 0.9% |
| NUS | NU SKIN ENTERPRISES, INC. | $235.6M | 1.5x | -14.3% |
| HWH | HWH International Inc. | $14.5M | — | -30.8% |
| MEDS | DataMeds AI, Inc. | $2.8M | — | 28.7% |
| HKPD | Cellyan Biotechnology Co., Ltd | — | — | — |